Search Within

Shanu Modi

  1. "Health Outcomes Research Group"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (6)
Groups
  1. Breast Medicine Service (22)
  2. Department of Medicine (22)
  3. Epidemiology and Biostatistics (22)
  4. Health Outcomes Research Group (22)
  5. Population Sciences Research Program (22)
  6. Solid Tumor Oncology Division (22)

More Groups

People
  1. Shari Goldfarb (22)
  2. Clifford Hudis (19)
  3. Diana Lake (19)
  4. Chau Dang (15)
  5. Maura Dickler (15)
  6. Monica Fornier (15)

More People

Years
  1. 2019 (3)
  2. 2018 (1)
  3. 2017 (3)
  4. 2016 (2)
  5. 2015 (3)
  6. 2014 (4)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Cancer Research (6)
  3. Annals of Oncology (2)
  4. Clinical Breast Cancer (2)
  5. JAMA Dermatology (2)
  6. JAMA Network Open (1)
Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (6)
  3. American Medical Association (3)
  4. Elsevier Inc. (2)
  5. Oxford University Press (2)

Results (22)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S. B.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; Comen, E. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save